Recode
Edge
A programmatic pre-seed fund backing the best founders solving the biggest healthcare problems with AI and deep tech.
AI is rebuilding healthcare problem by problem: drug discovery, diagnostics, immunology, cancer, regenerative medicine. The founders driving it sit in research labs at the world’s leading institutions, often years ahead of the venture market.
Edge finds them first, backs them at formation, and stays with them as they grow.
Reaching founders across the world's leading research universities.
Edge runs as cohorts,
not one-off deals.
We announce a programme and run targeted calls across the USA and Europe, inviting scientists building with AI and deep tech. A two-step process takes each application through video interviews and expert review. The strongest teams join the cohort.
We then write first cheques into the standout teams and keep backing them. Cohorts run on a schedule, not on luck. That gives us consistent first-cheque access to the best founders, ahead of institutional seed and Series A.
Every cohort goes through an intensive bootcamp
- A faculty of mentors and one-to-one sessions for every company
- Technical workshops with partners including OpenAI and AWS
- Hands-on support through the earliest, hardest months
Network
We are building the strongest network of research institutions and innovators leading at the intersection of AI and healthcare.
Early access
That network puts the best ideas in front of us years ahead of the market.
Future rounds
Backing winners at formation earns us a seat in their later rounds, as the category's leaders emerge.
Edge 1 demonstrated strong demand for early capital by exceptional teams
universities in outreach, with visits to leading sites
applications from 55+ global universities
companies selected for an intensive bootcamp
strategic partners: AWS, OpenAI and Eli Lilly
first cheques into standout companies, with continued Recode Ventures support
The cohort came from the best institutions in the world. Founders want what Edge offers, and Recode reaches talent others never see.
| COMPANY | INSTITUTIONS | FOCUS |
|---|---|---|
| Astir | UChicago | Drug discovery |
| Atom | Princeton, Duke | Cancer |
| Augment | Mass General, Harvard Medical School | Immunology |
| Kiragen | Harvard, MIT | Cancer |
| Misogi Labs | Paris-Saclay, Politecnico di Milano, Keio | Drug discovery |
| Motley | MIT, Harvard, Weill Cornell | Diagnostics |
| Orbits | University of Antwerp | Cancer |
| Organon | MIT | Regenerative medicine |
| PersonaDx | UChicago | Cancer |
| SyzOnc | Harvard, MIT, UPenn | Cancer |
